Genotoxic activity of four inhibitors of DNA topoisomerases in larval cells of Drosophila melanogaster as measured in the wing spot assay

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 413, Issue 2, 1998, Pages 191-203

  Torres, C ^a   Creus, A ^a   Marcos, R ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Drosophila; Genotoxicity; Mitotic recombination; Somatic mutation; Topoisomerase inhibitor

Indexed keywords

AMSACRINE; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; MESYLIC ACID ETHYL ESTER; NALIDIXIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; ENZYME INHIBITION; FORELIMB; GENETIC TOXICOLOGY; GENOTOXICITY; LARVA; NONHUMAN; PRIORITY JOURNAL; SOMATIC MUTATION;

AMSACRINE; ANIMALS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DROSOPHILA MELANOGASTER; ETOPOSIDE; LARVA; MUTAGENS; NALIDIXIC ACID;

EID: 0032536708     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5718(98)00031-X     Document Type: Article

References (51)

1. Zimmermann F.K., Schwaier R., Laer U.V. Mitotic recombination induced in Saccharomyces cerevisiae with nitrous acid, diethylsulfate and carcinogenic, alkylating nitrosamides. Z. Vererbungsl. 98:1966;230-246.
2. Würgler F.E. The importance of mitotic recombination in genetic toxicology. Rev. Toxicol. 6:1989;131-137.
3. Müller H., Scott R. Hereditary conditions in which the loss of heterozygosity may be important. Mutat. Res. 284:1992;15-24.
4. Würgler F.E. Recombination and gene conversion. Mutat. Res. 284:1992;3-14.
5. Hoffmann G.R. Induction of genetic recombination: Consequences and model systems. Environ. Mol. Mutagen. 23:1994;59-66.
6. F.E. Würgler, E.W. Vogel, In vivo mutagenicity testing using somatic cells of Drosophila melanogaster, in: F.J. De Serres (Ed.), Chemical Mutagens, Principles and Methods for their Detection, Plenum, New York, 1986, pp. 1-72.
7. Hoffmann G.R. Bacterial assays for recombinagens. Mutat. Res. 284:1992;125-146.
8. Sengstag C. The role of mitotic recombination in carcinogenesis. Crit. Rev. Toxicol. 24:1994;323-353.
9. Cavenee W.T., Koufos A., Hansen M.F. Recessive mutant genes predisposing to human cancer. Mutat. Res. 168:1986;3-14.
10. Ramel C. Short-term testing - are we looking at wrong endpoints? Mutat. Res. 205:1988;13-24.
11. Marshall C.J. Tumor suppressor genes. Cell. 64:1991;313-326.
12. Graf U., Würgler F.E. The somatic white-ivory eye spot test does not detect the same spectrum of genotoxic events as the wing somatic mutation and recombination test in Drosophila melanogaster. Environ. Mol. Mutagen. 27:1996;219-226.
13. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:1989;351-375.
14. Osheroff N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol. Ther. 41:1989;223-241.
15. Wang J.C., Caron P.R., Kim R.A. The role of DNA topoisomerases in recombination and genome stability: a double-edged sword? Cell. 62:1990;403-406.
16. Anderson R.D., Berger N.A. Mutagenicity and carcinogenicity of topoisomerase-interactive drugs. Mutat. Res. 309:1994;109-142.
17. D.L. Lindsley, G.G. Zimm (Eds.), The Genome of Drosophila melanogaster, Academic Press, San Diego, CA, USA, 1992.
18. Graf U., Frei H., Kägi A., Katz A.J., Würgler F.E. Thirty compounds tested in the Drosophila wing spot test. Mutat. Res. 222:1989;359-373.
19. Frei H., Würgler F.E. Statistical methods to decide whether mutagenicity test data from Drosophila assays indicate a positive, negative, or inconclusive result. Mutat. Res. 203:1988;297-308.
20. Frei H., Clements J., Howe D., Würgler F.E. The genotoxicity of the anti-cancer drug mitoxantrone in somatic and germ cells of Drosophila melanogaster. Mutat. Res. 279:1992;21-33.
21. Kastenbaum M.A., Bowman K.O. Tables for determining the statistical significance of mutation frequencies. Mutat. Res. 9:1970;527-549.
22. Alonso Moraga A., Graf U. Genotoxicity testing of antiparasitic nitrofurans in the Drosophila wing somatic mutation and recombination test. Mutagenesis. 4:1989;105-110.
23. Schlesinger R.B., Zelikoff J.T., Chen L.C., Kinney P.L. Assessment of toxicologic interactions resulting from acute inhalation exposure to sulfuric acid and ozone mixtures. Toxicol. Appl. Pharmacol. 115:1992;183-190.
24. Katsifis S.P., Kinney P.L., Hosselet S., Burns F.J., Christie N.T. Interaction of nickel with mutagens in the induction of sister chromatid exchanges in human lymphocytes. Mutat. Res. 359:1996;7-15.
25. Tripathy N.K., Würgler F.E., Frei A. Genetic toxicology of six carcinogens and six non-carcinogens in the Drosophila wing spot test. Mutat. Res. 242:1990;169-180.
26. M. Batiste-Alentorn, Estudio comparativo de distintos ensayos de mutación somática en Drosophila para la detección de agentes cancerígenos, PhD Thesis, Universitat Autònoma de Barcelona, 1994.
27. Frei H., Würgler F.E. Optimal experimental design and sample size for the statistical evaluation of data from somatic mutation and recombination tests (SMART) in Drosophila. Mutat. Res. 334:1995;247-258.
28. Frei H., Würgler F.E. Induction of somatic mutation and recombination by four inhibitors of eukaryotic topoisomerases assayed in the wing spot test of Drosophila melanogaster. Mutagenesis. 11:1996;315-325.
29. Drlica F., Franco R. Inhibitors of DNA topoisomerases. Biochemistry. 27:1988;2253-2259.
30. Ghosh R., Bhattacharjee S.B. Killing and mutation induced in quiescent V79 cells as influenced by nalidixic acid. Mutat. Res. 243:1990;7-12.
31. Summer A.T. Inhibitors of topoisomerases do not block the passage of human lymphocyte chromosomes through mitosis. J. Cell Sci. 103:1992;105-115.
32. Kowalezyk J. Sister chromatid exchanges in children treated with nalidixic acid. Mutat. Res. 77:1980;371-375.
33. Ribas G., Xamena N., Creus A., Marcos R. Sister-chromatid exchanges (SCE) induction by inhibitors of DNA topoisomerases in cultured human lymphocytes. Mutat. Res. 368:1996;205-211.
34. Ramel C., Magnusson J. Modulation of genotoxicity in Drosophila. Mutat. Res. 267:1992;221-227.
35. Gellert M. DNA topoisomerases. Annu. Rev. Biochem. 50:1981;879-910.
36. Andersson H.C., Kihlman B.A. The production of chromosomal alterations in human lymphocytes by drugs known to interfere with the activity of DNA topoisomerase II: I. m-AMSA. Carcinogenesis. 10:1989;123-130.
37. Pommier Y., Zwelling L.A., Shan C.K., Whang-Peng J., Bradley M.O. Correlations between intercalator-induced DNA strand breaks and sister-chromatid exchanges, mutations and cytotoxicity in Chinese hamster cells. Cancer Res. 45:1985;3143-3149.
38. Doerr C.L., Harrington-Brock K., Moore M.M. Micronucleus, chromosome aberrations, and small-colony TK mutant analysis to quantitate chromosomal damage in L5178Y mouse lymphoma cells. Mutat. Res. 222:1989;191-203.
39. Larripa I., de Pargament M.M., de Vinuesa M.L., Demattei A., de Salum B.S. In vivo and in vitro cytogenetic effects of the anti-tumor agent amsacrine (AMSA). Mutat. Res. 138:1984;87-91.
40. Kao-Shan C.S., Micetich K., Zwelling L.A., Whang-Peng J. Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro. Cancer Treat. Rep. 68:1984;989-997.
41. Backer L.C., Allen J.W., Harrington-Brock K., Campbell J.A., DeMarini D.M., Doerr C.L., Howard D.R., Kligerman A.D., Moore M.M. Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro. Mutagenesis. 5:1990;541-547.
42. Funayama Y., Nishio K., Wakabayashi K., Nagao M., Shimoi K., Ohira T., Hasegawa S., Saijo N. Effects of β- and γ-carboline derivatives on DNA topoisomerase activities. Mutat. Res. 349:1996;183-191.
43. C. Ramel, H. Cederberg, J. Magnusson, E. Vogel, A.T. Natarajan, L.H. Mullender, A. Szakmary, J.M. Nivard, J.M. Parry, M.A. Comendador, L.M. Sierra, J.A. Ferreiro, S. Consuegra, Somatic recombination, gene amplification and cancer, The STEP Programme Final Reports, Contact Group Meeting, Environmental Health and Chemical Safety, Noordwijkerhout (NL), 1995.
44. Pérez-Chiesa Y., Narvaez Z. Evaluation of genotoxicity of the indenoisoquinoline analogues of fagaronine and nitidine in Drosophila melanogaster. Mutat. Res. 301:1993;207-212.
45. Cortés F., Piñero J. Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells. Cancer Chemother. Pharmacol. 34:1994;411-415.
46. Mailhes J.B., Marchetti F., Phillips G.L. Jr., Barnhill D.R. Preferential pericentric lesions and aneuploidy induced in mouse oocytes by the topoisomerase II inhibitor etoposide. Teratogen. Carcinogen. Mutagen. 14:1994;39-51.
47. Zhang H., Wang J.C., Liu L.F. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc. Natl. Acad. Sci. U.S.A. 85:1988;1060-1064.
48. Kroeger P.E., Rowe T.C. Interaction of topoisomerase I with the transcribed region of the Drosophila HSP 70 heat shock gene. Nucleic Acids Res. 17:1989;8495-8509.
49. Wittig B., Dorbic T., Rich A. The level of Z-DNA in metabolically active permeabilized mammalian cell nuclei is regulated by torsional strain. J. Cell Biol. 108:1989;755-764.
50. Marec F., Socha R. Dose-response analysis of data obtained in the Drosophila wing spot test after ethyl methanesulfonate treatment. Acta Entomol. Bohemoslov. 84:1987;401-407.
51. Lim M., Liu L.F., Jacobson-Kram D., Williams J.R. Induction of sister chromatid exchanges by inhibitors of topoisomerases. Cell Biol. Toxicol. 2:1986;485-494.